top of page
Subscriber login:
SUBMIT
Remember me
Search
US Pharmaceutical Pipeline Expands With Innovation and Competition
A surge of generics, biosimilars, and innovative therapies are expected in 2025, addressing conditions from cancer to chronic diseases.
Apr 8
Further Dissecting the Launch of Adalimumab Biosimilars in the US
According to the IPD Analytics team, an adalimumab biosimilar launch may occur as early as late 2022.
Apr 21, 2021
bottom of page